Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (16143)	12/16/2002 11:16:41 PM
From: Bluegreen	Respond to of 17367

You know that kind of reminds me of..........Thomas Edison. You would of had a very good time counting his failures BUT even if he had ONLY came up with the lightbulb he still would of been a legend. Now that we have the half empty diary by you how about this...............look down the list under patient support. >>>>>>>>>>http://www.baxterhealthcare.co.uk/PatientSupport/PatientSupport.htm

To: Cacaito who wrote (16143)	12/23/2002 5:21:01 PM
From: Arthur Radley	Read Replies (2) \| Respond to of 17367

After such a long wait....XOMA has some positive news.... Welcome, PrintedWords [Sign Out] Money Manager - My Yahoo! View - Customize Financial News Enter symbol(s) BasicDayWatchPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup Press Release Source: Genentech Genentech and XOMA Submit Biologics License Application for FDA Approval of Raptiva -- Efalizumab -- for the Treatment of Moderate-to-Severe Plaque Psoriasis Monday December 23, 4:30 pm ET SOUTH SAN FRANCISCO, Calif. & BERKELEY, Calif.--(BUSINESS WIRE)--Dec. 23, 2002--Genentech, Inc. (NYSE: DNA - News) and XOMA Ltd. (Nasdaq: XOMA - News) today announced they have submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Raptiva(TM) (Efalizumab), a recombinant humanized monoclonal antibody under evaluation for the treatment of moderate-to-severe plaque psoriasis.